08.01.2024 • News
EuroAPI Appoints Ludwig de Mot as Chief Transformation Officer
EuroAPI has appointed Ludwig de Mot as chief transformation officer and executive vice president (EVP).
Contract Development And Manufacturing Organizations (CDMO)
20.12.2023 • News
Biosynth Acquires VIO Chemicals
Swiss Biosynth, a supplier of raw materials to the life science industry, has acquired VIO Chemicals, a Zurich, Switzerland-based company with leading chemical R&D expertise and a global network of large-scale manufacturing partners. Financial details of the transaction have not been disclosed.
14.12.2023 • News
Lucas Sauer-Jones Appointed as Vice President & General Manager of Veranova’s New England Sites
US API maker Veranova has appointed Lucas Sauer-Jones as the company’s vice president & general manager, New England. He will be responsible for Veranova’s sites in Devens and North Andover.
Unleashing CDMO Growth through Effective Pricing
In the rapidly evolving industry of contract development and manufacturing organizations (CDMOs), a well-defined pricing strategy is essential to drive growth and profitability. To stay ahead and participate in the expansion of the market, CDMOs need to transition to a structured value-based pricing approach that considers customer value, complexity, and specific needs.
22.11.2023 • News
EuroAPI Completes Acquisition of BianoGMP
EuroAPI has completed the acquisition of BianoGMP, a contract development and manufacturing organization (CDMO) specializing in oligonucleotides.
20.11.2023 • News
AGC Expands Production Capacity for Agrochemicals and Pharmaceuticals in Japan
AGC Wakasa Chemicals, part of Japanese group AGC, has completed a new large-scale production line at its Kaminaka Plant in Fukui prefecture, Japan, as it expects demand for agrochemicals and pharmaceuticals to grow steadily against a backdrop of population growth and improvement of living standards.
10.11.2023 • News
Olon to Nearly Double Production Capacity of Indian Site
Olon, an Italian CDMO and API producer of active pharmaceutical ingredients (APIs), plans to invest €10 million in a multi-year expansion of its production site in Mahad, India.
06.11.2023 • News
Noramco Acquires Drug Product Business Unit from Cambrex
Noramco, a US producer of active pharmaceutical ingredients (APIs), has completed the acquisition of the Cambrex drug product business unit previously known as Halo Pharmaceuticals. Financial details were not disclosed.
31.10.2023 • News
Aragen to Invest $30 Million in a New Indian Bio-Manufacturing Site
Aragen, an India, Hyderabad-headquartered contract research development and manufacturing organization (CRDMO) for small molecules and biologics, plans to set up a new biologics manufacturing facility in Bangalore, India.
26.10.2023 • News
Samsung Biologics Partners with Kurma for Biologics Development and Manufacturing
Samsung Biologics, a global contract development and manufacturing organization (CDMO), and Kurma Partners, a European venture capital firm in healthcare and biotechnology, recently announced a strategic partnership for the development and manufacturing of biologics for Kurma Partners’ portfolio companies.
26.10.2023 • News
EuroAPI Announces New Governance
EuroAPI's Board of Directors decided that Karl Rotthier would step down as CEO, effective October 30, 2023. They initiated the search for a new CEO and appointed Viviane Monges, the current Board Chair, as interim CEO until a permanent successor is found, while she continues her role as Board Chair.
25.10.2023 • News
Quotient Sciences Bolsters Sterile Fill/Finish Capacity
Quotient Sciences, a drug development and manufacturing accelerator, has invested significantly in expanding its sterile fill/finish capabilities at its Alnwick, UK facility. This expansion aims to meet the rising demand in the industry for comprehensive drug development programs by enhancing the capacity of the Annex 1-compliant facility.
16.10.2023 • News
Navin Fluorine International Launches New CDMO Division, Navin Molecular
Navin Fluorine International Ltd (NFIL), part of the Padmanabh Mafatlal Group, has unveiled the new identity for its contract development and manufacturing division, Navin Molecular. The brand is designed to meet the need for reliable, fast, and cost-effective custom synthesis and manufacturing services for the pharmaceutical and speciality chemicals industries.
11.10.2023 • News
Olon Opens New Proteins Manufacturing Site in Italy
Olon Biotech, a division of Italian API producer Olon, has inaugurated a new facility for the industrial-scale production of proteins from alternative sources at its site in Settimo, Italy. Olon pegged the investment in the new plant at €70 million.
06.10.2023 • News
Lonza Increases Capacity for Antibody-Drug Conjugates at Visp, Switzerland
Swiss contract development and manufacturing organization (CDMO) Lonza is extending a long-term collaboration with an unnamed major global biopharmaceutical partner. Under the agreement, the current dedicated bioconjugation capacity will be increased fourfold by adding two new bioconjugation suites for the commercial supply of antibody-drug conjugates (ADCs) at Lonza's site in Visp, Switzerland.
04.10.2023 • News
AmbioPharm Appoints Brian Gregg as CEO
Contract development and manufacturing organization (CDMO) AmbioPharm has appointed industry veteran Brian Gregg as CEO. Gregg, who has more than 30 years of experience in the peptide CDMO industry, succeeds Tim Nieters, who will be stepping down after seven years with the company.
25.09.2023 • News
Veranova Appoints William Sanders as Global VP of Chemical Development Operations
US contract development and manufacturing organization (CDMO) Veranova has appointed William Sanders as global vice president of chemical development operations, effective Sep. 18, 2023.
15.09.2023 • News
Sanner Group Opens Second Manufacturing Facility in China
Sanner, a German contract manufacturing and development organization (CDMO), is expanding its production capacity in the Asia-Pacific region with the opening of a second manufacturing facility in Kunshan, China.
15.09.2023 • News
Ian Fuller Appointed as Vice President of Operations at CMO Jubilant HollisterStier
North American contract manufacturer Jubilant HollisterStier has appointed Ian Fuller as its new vice president of Operations.
How CDMOs Can Contribute to Pharma Supply even Better
The demand for medicines is increasing rapidly and R&D pipelines have doubled over the last decade.
New Biologics and Advanced Therapies
The pharmaceutical market is undergoing a profound transformation, driven by innovation among biologics and advanced therapies (ATs). This shift is not only redefining the treatment landscape but also presenting new opportunities and challenges related to the drug development and manufacturing value chain.
The Evolution of CDMOs
Contract development and manufacturing organizations (CDMOs) are a crucial part of the life sciences industry. Strangely, despite its current prominence, the CDMO industry is a relatively young one. There have been significant developments over its short lifespan, and it is likely that we see even more growth in the years to come.
06.09.2023 • News
CordenPharma Completes Upgrade of US Peptide Production Site in Colorado
CDMO CordenPharma, a specialist in active pharmaceutical ingredients (APIs), excipients, drug products and packaging services, inaugurated an increased commercial peptide production capacity with newly-upgraded facilities at its Colorado site in the US, which the company says is the world's largest solid-phase peptide synthesis (SPPS) manufacturing facility.
05.09.2023 • News
Lonza, Vertex Break Ground on New US Cell Therapy Plant
Last week, Lonza and Vertex Pharmaceuticals broke ground on a new US facility in Portsmouth, New Hampshire, to manufacture cell therapies for diabetes.
29.08.2023 • News
EuroAPI to Acquire German CDMO BianoGMP
Active pharmaceutical ingredients manufacturer EuroAPI has agreed to acquire BianoGMP, a contract development and manufacturing organization (CDMO) specializing in oligonucleotides. Biano is to become a EuroAPI company but retain its corporate brand.
01.08.2023 • News
Finnish CDMO Biovian Expands its Facility in Turku
Finnish contract development and manufacturing organization (CDMO) Biovian, specializing in biopharmaceuticals, is investing more than €50 million to expand its manufacturing facility in Turku, Finland.
17.07.2023 • News
Upperton Completes Construction of New Development and Manufacturing Site
Upperton Pharma Solutions, a UK contract development and manufacturing organization (CDMO), has completed construction of its new development and GMP manufacturing headquarters in Nottingham, UK. The company said it has invested £15 million in the new 50,000-square-foot facility.
Expanding Expertise in Highly-Potent APIs
After acquiring the two Catalonian sites in Barberà del Vallès and El Masnou about two years ago, Siegfried is now significantly expanding its expertise in the production of complex Drug Products containing Highly-Potent APIs (HPAPIs). In addition, the company has opened a new development center for oral solid dosage forms with active ingredients and HPAPIs as well as for ophthalmic sterile products. This not only strengthens Siegfried's position in the area of drug products, but also its global network and international competitiveness.
Increasing the Sustainability of API Production
For Siegfried, sustainability is much more than a phrase with a green coating. The term, which encompasses social and economic criteria in addition to ecological aspects, is one of five central corporate values. One of the biggest levers for reducing energy and resource consumption in the pharma supply chain lies in the efficient production of active ingredients and pharmaceuticals. The company therefore works consistently on optimizing its processes.
Small Substances with Big Effects
The market for APIs is expanding significantly. Experts predict annual growth rates between 4.5 and 7.6 percent by 2029. There are plenty of good reasons for this: Chronic diseases are on the rise - and with them the need for medicines and active ingredients. In addition, the economic upswing in several emerging countries means that more people can afford novel medicines. APIs are also benefiting from the trend toward personalized medicine and the growing understanding of diseases. Meanwhile, API developers and manufacturers are working on increasingly sophisticated methods to better handle these delicate substances.
Opportunities and Limits of Sustainability
The Pharmaceutical industry must prioritize sustainability. Jürgen Roos, Chief Scientific Officer (CSO) of Siegfried, explains opportunities and limits of sustainability.
07.06.2023 • Whitepaper • Strategy
Special Issue: Swiss CDMO Siegfried Celebrates 150th Anniversary
There are only a few chemical and pharmaceutical companies that look back at a history of 150 years. Certainly, many companies claim such a long legacy, but if you only count those that have been operating and thriving under the same name for a century and a half, the number boils down significantly.
Sustainability – The Many Facets of Action
Climate change, energy crisis, the call for a more environmentally compatible production method and socially responsible action do not stop at the pharmaceutical and biotech industries. Sustainability is becoming a central competitive and reputation factor and carries a high economic value. This need not be to the industry´s disadvantage. It helps companies to make processes more efficient, reduces energy consumption and keeps costs in check. But is the pharmaceutical industry already doing enough in this regard?
Siegfried Demonstrates Biologics Expertise in Hameln
The Fill & Finish of biologic drugs is expensive and poses special technological challenges for CDMOs. At the German site in Hameln, Siegfried has successfully proven these capabilities over the past two years by producing Covid-19 vaccines and a significant number of clinical batches for several biological companies. By investing in its competencies, capacities and flexibility, the company intends to further expand this demanding but promising business area.
"We Want to Be a Big Fish"
The CDMO (contract development and manufacturing organizations) business has a bright future, of that Siegfried CEO Wolfgang Wienand is certain. The economic advantages alone speak for this compared to in-house production by the pharmaceutical companies themselves. Although Siegfried has already reached sufficient critical size within its industry, he sees the company continuing on its growth path. The goal is to take over an even larger share of the value chain from pharmaceutical companies in the future.
Suanfarma
DSM Pharmaceutical Products
Society of Chemical Manufacturers & Affiliates (SOCMA)
Kurma Partners
AmbioPharm, Inc.
Fraser Dove International
Siegfried
OneSource Specialty Pharma Limited
Aurigene Pharmaceutical Services Ltd.
Aenova Holding GmbH
Alcami Corporation
Samsung Biologics
ISPE D/A/CH e.V.
CPA Chemical Pharmac. Ass.
Codexis
Lonza AG
SchüllerConsulting
SOCMA Society of Chemical
Dottikon Exclusive Synthesis AG
Syngene International Ltd.
Curia
FDA Smart
Fujifilm
Sterling Pharma Solutions
CatSci Ltd.
GLSyntech LLC
Olon S.p.A.
Simon-Kucher & Partners Strategy & Marketing Consultants GmbH
Microinnova Engineering GmbH
J. Rettenmaier & Söhne GmbH + Co KG
Thomson Reuters
Alira Health S.r.l.
Global Gateway Advisors
Hovione
Solvias AG
Bio Evaluation
Camelot Management Consultants AG
PP Consulting
GBI Research
DCAT - Drug, Chemical & Associated Technologies Association
Avantor
EuroAPI
Catalent Inc.
Ferak Berlin GmbH
Cambrex Corporation
Veranova
Arxada AG
CMS Advisors GmbH & Co. KG
HAS Healthcare Advanced Synthesis SA
ICIG